España
India
Italia
대한민êµ
日本
My Account
Benzinga Edge
Benzinga Research
Benzinga Pro
Login
Get Benzinga Pro
Data & APIs
Events
Premarket
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Oculis Holding
OCS
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$22.35
0.20
0.90%
At close: -
$22.35
0.00
0.00%
After Hours: 9:27 AM EDT
Get Report
Comment
Oculis Holding (OCS) Forecast
News
Earnings
Oculis Holding (OCS) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Oculis Holding (NASDAQ:OCS) Stock
Oculis Holding Stock (NASDAQ: OCS)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Friday, January 10, 2025
TD Synnex, Walgreens, Savers Value Village And Other Big Stocks Moving Higher On Friday
Avi Kapoor
Tuesday, January 07, 2025
Chardan Capital Maintains Buy on Oculis Holdi...
Benzinga Newsdesk
Monday, January 06, 2025
HC Wainwright & Co. Reiterates Buy on Oculis ...
Benzinga Newsdesk
Oculis' OCS-05 Reveals Phase 2 ACUITY Trial R...
Benzinga Newsdesk
Monday, November 11, 2024
HC Wainwright & Co. Reiterates Buy on Oculis ...
Benzinga Newsdesk
Thursday, November 07, 2024
Oculis Holding Q3 2024 Adj. EPS CHF(0.48) Bea...
Benzinga Newsdesk
Wednesday, October 23, 2024
HC Wainwright & Co. Reiterates Buy on Oculis ...
Benzinga Newsdesk
Monday, October 21, 2024
Oculis shares are trading higher after the co...
Benzinga Newsdesk
Oculis Expands DIAMOND Program with Global Re...
Benzinga Newsdesk
Tuesday, October 15, 2024
Oculis Showcases Results for Diabetic Eye Tre...
Benzinga Newsdesk
Wednesday, August 28, 2024
HC Wainwright & Co. Reiterates Buy on Oculis ...
Benzinga Newsdesk
Tuesday, August 27, 2024
Oculis Holding shares are trading higher afte...
Benzinga Newsdesk
Oculis Holding Q2 2024 Adj. EPS CHF(0.51) Mis...
Benzinga Newsdesk
Monday, July 15, 2024
AutoNation, Baxter International And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Avi Kapoor
Tuesday, June 11, 2024
Chardan Capital Reiterates Buy on Oculis Hold...
Benzinga Newsdesk
Alphabet To Rally Over 28%? Here Are 10 Top Analyst Forecasts For Tuesday
Avi Kapoor
B of A Securities Maintains Buy on Oculis Hol...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Oculis H...
Benzinga Newsdesk
Baird Maintains Outperform on Oculis Holding,...
Benzinga Newsdesk
Monday, June 10, 2024
Oculis Announces Topline Results From Its Pha...
Benzinga Newsdesk
Thursday, May 30, 2024
HC Wainwright & Co. Reiterates Buy on Oculis ...
Benzinga Newsdesk
Monday, May 13, 2024
HC Wainwright & Co. Reiterates Buy on Oculis ...
Benzinga Newsdesk
Wednesday, May 08, 2024
Oculis Holding Q1 EPS $(0.50) Misses $(0.41) ...
Benzinga Newsdesk
Oculis Announces Completion Of Enrollment In ...
Benzinga Newsdesk
Wednesday, April 24, 2024
HC Wainwright & Co. Maintains Buy on Oculis H...
Benzinga Newsdesk
Tuesday, March 19, 2024
Chardan Capital Maintains Buy on Oculis Holdi...
Benzinga Newsdesk
Baird Maintains Outperform on Oculis Holding,...
Benzinga Newsdesk
Monday, March 18, 2024
Oculis's 2023 Cash, Cash Equivalents, And Sho...
Benzinga Newsdesk
Oculis Holding Q4 GAAP EPS CHF(0.34) Up From ...
Benzinga Newsdesk
Wednesday, March 06, 2024
Wedbush Reiterates Outperform on Oculis Holdi...
Benzinga Newsdesk
Thursday, February 29, 2024
HC Wainwright & Co. Reiterates Buy on Oculis ...
Benzinga Newsdesk
Wednesday, February 28, 2024
Oculis Updates On Late-Stage Clinical Trials ...
Benzinga Newsdesk
Friday, December 29, 2023
FLJ Group, Bit Digital And Other Big Stocks Moving Higher In Friday's Pre-Market Session
Avi Kapoor
Wednesday, December 20, 2023
Oculis Announces First Patient First Visit In...
Benzinga Newsdesk
Monday, December 18, 2023
Oculis Announces First Patient First Visit in...
Benzinga Newsdesk
Thursday, December 07, 2023
Oculis Announces First Patient First Visit (F...
Benzinga Newsdesk
Tuesday, December 05, 2023
Chardan Capital Initiates Coverage On Oculis ...
Benzinga Newsdesk
Friday, November 17, 2023
Expert Ratings for Oculis Holding
Benzinga Insights
Wedbush Reiterates Outperform on Oculis Holdi...
Benzinga Newsdesk
Thursday, October 05, 2023
Benzinga's Top Ratings Upgrades, Downgrades For October 5, 2023
Benzinga Insights
What 4 Analyst Ratings Have To Say About Oculis Holding
Benzinga Insights
Stifel Initiates Coverage On Oculis Holding w...
Benzinga Newsdesk
Wednesday, August 30, 2023
Expert Ratings for Oculis Holding
Benzinga Insights
B of A Securities Maintains Buy on Oculis Hol...
Benzinga Newsdesk
HC Wainwright & Co. Reiterates Buy on Oculis ...
Benzinga Newsdesk
Tuesday, August 08, 2023
Oculis Holding AG Announces Phase 3 OPTIMIZE ...
Benzinga Newsdesk
Thursday, August 03, 2023
HC Wainwright & Co. Reiterates Buy on Oculis ...
Benzinga Newsdesk
Wednesday, August 02, 2023
Oculis Holding AG Announces First Patient Enrolled In LEOPARD, An Investigator-Initiated Trial, With OCS-01 Eye Drops For The Treatment Of Cystoid Macular Edema
Happy Mohamed
Wednesday, June 14, 2023
Benzinga's Top Ratings Upgrades, Downgrades For June 14, 2023
Benzinga Insights
B of A Securities Initiates Coverage On Oculi...
Benzinga Newsdesk
Show More
